Prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats by 1α-hydroxyvitamin D5

被引:46
作者
Mehta, R
Hawthorne, M
Uselding, L
Albinescu, D
Moriarty, R
Christov, K
Mehta, R
机构
[1] Univ Illinois, Coll Med, Dept Surg Oncol, Chicago, IL 60612 USA
[2] Univ Illinois, Coll Arts & Sci, Dept Chem, Chicago, IL 60612 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2000年 / 92卷 / 22期
关键词
D O I
10.1093/jnci/92.22.1836
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although the active form of vitamin D, i.e., 1,25-dihydroxyvitamin D-3, is a potent cell-differentiating agent, its use in cancer prevention or therapy is precluded because it induces excessive blood calcium levels (hypercalcemia), However, less calcemic or noncalcemic synthetic analogues of vitamin D-3 are poorly effective against mammary carcinogenesis. We synthesized an analogue of vitamin D-5, l alpha -hydroxy-24-ethylcholecalciferol (1 alpha -hydroxyvitamin D-5), which was less calcemic than 1,25-dihydroxyvitamin D-3 and prevented the development of precancerous lesions in mammary glands. Here, we evaluate its efficacy in an experimental rat mammary carcinogenesis model. Methods: Sprague-Dawley rats were treated with 1 alpha -hydroxyvitamin D-5 beginning 2 weeks before carcinogen treatment. Animals received an intravenous injection of N-methyl-N-nitrosourea at 80 days of age and continued to receive dietary 1 alpha -hydroxyvitamin D-5 for an additional 105 days, Tumor incidence and multiplicity were determined, and plasma concentrations of calcium and phosphorus were measured. The efficacy of 1 alpha -hydroxyvitamin D-5 at different stages of carcinogenesis was determined in mouse mammary gland organ culture. All statistical tests were two-sided. Results: The tumor incidence was reduced from 80% (95% confidence interval [CI] = 51.9%-95.7%) in control rats to 53.3% (95% CI = 26.6%-78.8%) and 46.6% (95% CI = 21.3%-73.4%) in rats treated with 1 alpha -hydroxyvitamin D-5 at 25 mug/kg diet and 50 mug/kg diet, respectively. The tumor multiplicity was reduced from 1.6 tumors per rat to 1.2 (95% CI for the difference = -0.45 to 1.25; P = .34) and 0.8 (95% CI for the difference = 0.14-1.46; P = .02), respectively. There was no statistically significant increase in the plasma calcium or phosphorus concentration at either dose level. The vitamin D-5 analogue was effective during both the initiation and the promotion stages of mammary Lesion formation in organ culture, Conclusion: Our findings indicate that 1 alpha -hydroxyvitamin D-5 reduces the incidence of mammary carcinogenesis in vivo. This analogue appears to be a good candidate for further development as a chemopreventive agent.
引用
收藏
页码:1836 / 1840
页数:5
相关论文
共 18 条
[1]  
ANZANO MA, 1994, CANCER RES, V54, P1653
[2]   STRUCTURE-FUNCTION-RELATIONSHIPS IN THE VITAMIN-D ENDOCRINE SYSTEM [J].
BOUILLON, R ;
OKAMURA, WH ;
NORMAN, AW .
ENDOCRINE REVIEWS, 1995, 16 (02) :200-257
[3]  
DeLuca H F, 1986, Adv Exp Med Biol, V196, P361
[4]  
GRUBBS CJ, 1983, J NATL CANCER I, V70, P209
[5]  
Hisatake J, 1999, CANCER RES, V59, P4023
[6]   EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro [J].
James, SY ;
Mercer, E ;
Brady, M ;
Binderup, L ;
Colston, KW .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (05) :953-962
[7]  
KELLOFF GJ, 1993, J CELL BIOCHEM, P2
[8]  
Kinghorn AD, 1998, CURR ORG CHEM, V2, P597
[9]   Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo [J].
Koshizuka, K ;
Koike, M ;
Asou, H ;
Cho, SK ;
Stephen, T ;
Rude, RK ;
Binderup, L ;
Uskokovic, M ;
Koeffler, HP .
BREAST CANCER RESEARCH AND TREATMENT, 1999, 53 (02) :113-120
[10]   Induction of differentiation by 1α-hydroxyvitamin D5 in T47D human breast cancer cells and its interaction with vitamin D receptors [J].
Lazzaro, G ;
Agadir, A ;
Qing, W ;
Poria, M ;
Mehta, RR ;
Moriarty, RM ;
Das Gupta, TK ;
Zhang, XK ;
Mehta, RG .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (06) :780-786